

RESEARCH ADVISORY PANEL OF CALIFORNIA

<https://oag.ca.gov/research>

MEETING NOTICE & AGENDA

The Research Advisory Panel of California (“RAPC”) will hold a public meeting at the following date and time at the location identified below and via video and telephone conference:

Date: June 19, 2026

Time: 1:30 pm (Pacific)

NOTE: Please be advised, in accordance with Health and Safety Code section 11480.5, subd. (a), as amended by California Assembly Bill (AB) 1103 (Ward) (2025), and Government Code section 11123.5, RAPC will conduct this meeting by videoconference and teleconference. Every participating member of RAPC will attend this meeting remotely by videoconference. Members of the public may attend this meeting by teleconference, videoconference, or at the primary physical location, as described below.

To join by videoconference:

Link: <https://doj-ca.zoomgov.com/j/1616115547>

To join by teleconference:

Dial: 669 254 5252 or 669 216 1590

Webinar ID: 1616115547

Primary physical location:

California Department of Justice
1300 I Street, Tenth Floor, Room 1042
Sacramento, CA 95814

NOTE: Please be advised that Zoom may require attendees to input a name and an email address in order to attend a videoconference. You may use a pseudonym and a pseudonymous email if you would prefer not to use your name. You may also attend by telephone without giving a name (though your phone number will be visible to the panelists and RAPC staff).

MEETING AGENDA

OPEN SESSION

1. **Call to Order, Establishment of a Quorum, and General Announcements**
2. **Approval of Panel Meeting Minutes - April 10, 2026**
3. **Schedule II Controlled Substances in Non-Human Research**

CLOSED SESSION

4. **Review and possible approval of proposed studies involving controlled substances**
 Closed session pursuant to Government Code section 11126, subd. (c)(20), as amended by California AB 1103 (Ward) (2025) – *Discussion, review, and potential approval of four proposed human research projects into the nature and effects of cannabis or Schedule I or Schedule II controlled substances. Each proposed research project is under review by a RAPC subcommittee and contains sensitive and confidential information, the public disclosure of which is prohibited by law.*
 - a) Application No. PR#202614H. Applicant's Institution: UC San Francisco
 - b) Application No. PR#202615C. Applicant: Transcend Therapeutics
 - c) Application No. PR#202618H. Applicant: UC San Francisco
 - d) Application No. PR#202620S. Applicant: UC San Francisco

5. **Review and possible approval of proposed studies involving controlled substances**
 Closed session pursuant to Government Code section 11126, subd. (c)(20), as amended by California AB 1103 (Ward) (2025) – *Discussion, review, and potential approval of seven proposed non-human research projects into the nature and effects of cannabis or Schedule I or Schedule II controlled substances. Each proposed research project is under review by RAPC and contains sensitive and confidential information, the public disclosure of which is prohibited by law.*
 - a) Application No. PR#202610N. Applicant's Institution: UC Irvine
 - b) Application No. PR#202611N. Applicant's Institution: UC San Diego
 - c) Application No. PR#202612N. Applicant's Institution: University of Southern California
 - d) Application No. PR#202613N. Applicant's Institution: Cal State Polytechnic University
 - e) Application No. PR#202616N. Applicant: Pace Pharmaceuticals
 - f) Application No. PR#202617N. Applicant: Lin Zhi International, Inc.
 - g) Application No. PR#202619N. Applicant's Institution: University of British Columbia

6. **Review and possible approval of proposed studies involving controlled substances**
 Closed session pursuant to Government Code section 11126, subd. (c)(20), as amended by California AB 1103 (Ward) (2025) – *Discussion, review, and potential approval of thirteen amended human research projects into the nature and effects of cannabis or Schedule I or Schedule II controlled substances. Each proposed research project is under review by RAPC and contains sensitive and confidential information, the public disclosure of which is prohibited by law.*
 - a) Application No. PR#202403C. Applicant: Usona

- b) Application No. PR#202407H. Applicant's Institution: UC Los Angeles
- c) Application No. PR#202423C. Applicant: Definium
- d) Application No. PR#202428H. Applicant's Institution: Stanford University
- e) Application No. PR#202436C. Applicant: Definium
- f) Application No. PR#202506C. Applicant: Definium
- g) Application No. PR#202609C. Applicant: Definium
- h) Application No. PR#202516C. Applicant: Cybin
- i) Application No. PR#202525C. Applicant: Cybin
- j) Application No. PR#202230H. Applicant's Institution: UC San Francisco
- k) Application No. PR#202112H. Applicant's Institution: UC San Francisco
- l) Application No. PR#202531C. Applicant's Institution: Columbia University
- m) Application No. PR#202323H. Applicant's Institution: Stanford University

7. Review and possible approval of proposed studies involving controlled substances

Closed session pursuant to Government Code section 11126, subd. (c)(20), as amended by California AB 1103 (Ward) (2025) – *Discussion, review, and potential approval of zero amended non-human research projects into the nature and effects of cannabis or Schedule I or Schedule II controlled substances. Each proposed research project is under review by RAPC and contains sensitive and confidential information, the public disclosure of which is prohibited by law.*

- a) None.

OPEN SESSION

8. Adjournment

(See Notice to the Public, next page)

NOTICE TO THE PUBLIC

Agenda items may be discussed and actions taken out of order at the discretion of the Chairperson for convenience, to accommodate speakers, and to maintain a quorum. Action may be taken on any item on the agenda.

Public Comment: Members of the public who are attending will be given the opportunity to make comments on each agenda item prior to any action. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Total time allocated for public comment may be limited. Comments will be limited to three minutes per person; however, the Chairperson may decide to shorten or lengthen the public comment period at his or her discretion. Members of the public will not be permitted to "yield" their allotted time to other members of the public to make comments.

Accessibility: RAPC complies with the Americans with Disabilities Act by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the members of RAPC is available to the public in appropriate alternative formats when requested. If you need assistance, including disability-related modifications or accommodations to participate in this meeting, please make your request by contacting RAPC Executive Officer Tanveer Khan at (916) 210-5382, RAPC@doj.ca.gov, or 4949 Broadway, Sacramento, CA 95820. Requests must be received at least five business days before the meeting to ensure availability of the requested accommodation.

For the meeting notice and agenda and more information, please access RAPC's website at <https://oag.ca.gov/research>. Please direct requests for further information to RAPC Executive Officer Tanveer Khan, at (916) 210-5382, RAPC@doj.ca.gov, 4949 Broadway, Sacramento, CA 95820.

More information regarding research studies reviewed by RAPC in 2024 can be found at: <https://oag.ca.gov/system/files/media/rpc-2024-annual-report-final.pdf>.